Estrella Immunopharma Stock Performance
| ESLA Stock | 1.38 0.05 3.50% |
The firm shows a Beta (market volatility) of -0.5, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Estrella Immunopharma are expected to decrease at a much lower rate. During the bear market, Estrella Immunopharma is likely to outperform the market. At this point, Estrella Immunopharma has a negative expected return of -0.44%. Please make sure to confirm Estrella Immunopharma's day median price, period momentum indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if Estrella Immunopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Estrella Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN | 12/03/2025 |
2 | Estrella Immunopharma, Inc. Announces 8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules | 01/05/2026 |
3 | Estrella Immunopharma receives Nasdaq notice for delayed annual meeting By Investing.com - Investing.com Canada | 01/13/2026 |
4 | Estrella Immunopharma Upgraded at Wall Street Zen | 02/03/2026 |
5 | ESLA 100 percent CR Rate in Phase 12 Trial of EB103 in Aggressive B Cell NHL | 02/09/2026 |
| Begin Period Cash Flow | 9 M | |
| Total Cashflows From Investing Activities | 5 M |
Estrella Immunopharma Relative Risk vs. Return Landscape
If you would invest 220.00 in Estrella Immunopharma on November 13, 2025 and sell it today you would lose (82.00) from holding Estrella Immunopharma or give up 37.27% of portfolio value over 90 days. Estrella Immunopharma is currently does not generate positive expected returns and assumes 8.3384% risk (volatility on return distribution) over the 90 days horizon. In different words, 74% of stocks are less volatile than Estrella, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Estrella Immunopharma Target Price Odds to finish over Current Price
The tendency of Estrella Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.38 | 90 days | 1.38 | about 66.91 |
Based on a normal probability distribution, the odds of Estrella Immunopharma to move above the current price in 90 days from now is about 66.91 (This Estrella Immunopharma probability density function shows the probability of Estrella Stock to fall within a particular range of prices over 90 days) .
Estrella Immunopharma Price Density |
| Price |
Predictive Modules for Estrella Immunopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Estrella Immunopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Estrella Immunopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Estrella Immunopharma is not an exception. The market had few large corrections towards the Estrella Immunopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Estrella Immunopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Estrella Immunopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | -0.5 | |
σ | Overall volatility | 0.48 | |
Ir | Information ratio | -0.08 |
Estrella Immunopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Estrella Immunopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Estrella Immunopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Estrella Immunopharma generated a negative expected return over the last 90 days | |
| Estrella Immunopharma has high historical volatility and very poor performance | |
| Estrella Immunopharma may become a speculative penny stock | |
| Estrella Immunopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Estrella Immunopharma generates negative cash flow from operations | |
| Estrella Immunopharma has a poor financial position based on the latest SEC disclosures | |
| About 70.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: ESLA 100 percent CR Rate in Phase 12 Trial of EB103 in Aggressive B Cell NHL |
Estrella Immunopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Estrella Stock often depends not only on the future outlook of the current and potential Estrella Immunopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Estrella Immunopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.7 M | |
| Cash And Short Term Investments | 916.9 K |
Estrella Immunopharma Fundamentals Growth
Estrella Stock prices reflect investors' perceptions of the future prospects and financial health of Estrella Immunopharma, and Estrella Immunopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Estrella Stock performance.
| Return On Equity | -2.68 | ||||
| Return On Asset | -1.01 | ||||
| Current Valuation | 58.27 M | ||||
| Shares Outstanding | 37.07 M | ||||
| Price To Book | 241.30 X | ||||
| EBITDA | (8.85 M) | ||||
| Net Income | (8.85 M) | ||||
| Total Debt | 3 M | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (7.64 M) | ||||
| Earnings Per Share | (0.24) X | ||||
| Market Capitalization | 81.54 M | ||||
| Total Asset | 3.14 M | ||||
| Retained Earnings | (23.93 M) | ||||
| Working Capital | 4.27 M | ||||
About Estrella Immunopharma Performance
By analyzing Estrella Immunopharma's fundamental ratios, stakeholders can gain valuable insights into Estrella Immunopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Estrella Immunopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Estrella Immunopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.24) | (3.08) | |
| Return On Capital Employed | (70.78) | (67.24) | |
| Return On Assets | (3.24) | (3.08) | |
| Return On Equity | (70.79) | (67.25) |
Things to note about Estrella Immunopharma performance evaluation
Checking the ongoing alerts about Estrella Immunopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Estrella Immunopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Estrella Immunopharma generated a negative expected return over the last 90 days | |
| Estrella Immunopharma has high historical volatility and very poor performance | |
| Estrella Immunopharma may become a speculative penny stock | |
| Estrella Immunopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Estrella Immunopharma generates negative cash flow from operations | |
| Estrella Immunopharma has a poor financial position based on the latest SEC disclosures | |
| About 70.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: ESLA 100 percent CR Rate in Phase 12 Trial of EB103 in Aggressive B Cell NHL |
- Analyzing Estrella Immunopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Estrella Immunopharma's stock is overvalued or undervalued compared to its peers.
- Examining Estrella Immunopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Estrella Immunopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Estrella Immunopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Estrella Immunopharma's stock. These opinions can provide insight into Estrella Immunopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Estrella Stock analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |